Effects of subcutaneous pasireotide on cardiac repolarization in healthy volunteers: A single-center, phase I, randomized, four-way crossover study
Version of Record online: 16 NOV 2013
© 2013 The Authors. The Journal of Clinical Pharmacology Published by Wiley Periodicals, Inc. on behalf of The American College of Clinical Pharmacology
This is an open access article under the terms of the Creative Commons Attribution-NonCommercial License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.
The Journal of Clinical Pharmacology
Volume 54, Issue 1, pages 75–86, January 2014
How to Cite
Breitschaft, A., Hu, K., Darstein, C., Ligueros-Saylan, M., Jordaan, P., Song, D., Hudson, M. and Shah, R. (2014), Effects of subcutaneous pasireotide on cardiac repolarization in healthy volunteers: A single-center, phase I, randomized, four-way crossover study. Journal of Clinical Pharma, 54: 75–86. doi: 10.1002/jcph.213
- Issue online: 2 JAN 2014
- Version of Record online: 16 NOV 2013
- Accepted manuscript online: 25 OCT 2013 04:50AM EST
- Manuscript Accepted: 17 OCT 2013
- Manuscript Received: 20 JUN 2013
- Novartis Pharma AG
- Novartis Pharmaceuticals Corporation
Additional supporting information may be found in the online version of this article at the publisher's web-site.
Table S1. Summary of ΔΔQTcI (90% CI) for QTcI on Day 5 for Both Doses of Pasireotide and Moxifloxacin at Each Time Point
Table S2. Summary of ΔΔQTcI (90% CI) for QTcI, QTcF, PR and HR by Gender for Both Doses of Pasireotide up to 8 Hours Post-Dose
Table S3. Summary of Pharmacokinetic Parameters for Day 5
Table S4. Most Frequent AEs (≥5% of Subjects in Any Treatment Group), Regardless of Study Drug Relationship
Please note: Wiley Blackwell is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.